Protopic
ApprovedSmall molecule
AstellasProtopic is one of 78 small molecule programs targeting Atopic Dermatitis. It is currently in Approved.
3
Indications
3
Total Trials
0
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Nereus
VVanda Pharmaceuticals
Phase 3
Celestone
SSchering-Plough
Phase 3
Tagamet
DDT MedTech, LLC
Phase 3
Bepreve
BBausch Health Americas, Inc.
Phase 3
Protopic
AstellasApproved
Elidel
BayerPhase 3
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
OPA-15406
OtsukaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Seborrheic Dermatitis1 trial
Atopic Dermatitis1 trial
Vitiligo1 trial
Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control
Terminated·—·Phase 2/3·NCT01841008·35 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Protopic. EMBL-EBI & Wellcome Sanger Institute.
- [4]